Castilla Catalán, JesúsNavascués, AnaCasado, ItziarPérez-García, AlejandraAguinaga, AitziberEzpeleta, GuillermoPozo Sanchez, FranciscoEzpeleta, CarmenMartínez-Baz, Iván2020-01-302020-01-302018Euro Surveill. 2018 Feb;23(7).1560-7917http://hdl.handle.net/20.500.12105/8993The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.engVoRhttp://creativecommons.org/licenses/by/4.0/Case-control studyInfluenzaInfluenza vaccineInfluenza-like illnessRepeated vaccinationVaccine effectivenessAdolescentAdultAgedCase-Control StudiesChildChild, PreschoolFemaleHumansInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza VaccinesInfluenza, HumanMaleMiddle AgedSpainVaccinationYoung AdultSeasonsSentinel SurveillanceAtribución 4.0 Internacional2947162423710.2807/1560-7917.ES.2018.23.7.18-000571560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access